World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
64
Citations
17119
World Ranking
2915
National Ranking
1373

Jeffrey J. Molldrem publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jeffrey J. Molldrem sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 343 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jeffrey J. Molldrem D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey J. Molldrem sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 64 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2014 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Jeffrey J. Molldrem is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with significant publication contributions in Immunology, Hematology, Oncology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

Their work focuses on multiple key areas including CAR-T cell therapy research, Immunotherapy and Immune Responses, Acute Myeloid Leukemia Research, Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction, Hematopoietic Stem Cell Transplantation, and Acute Lymphoblastic Leukemia research.

Jeffrey J. Molldrem has authored numerous papers, with notable recent publications such as:

  • Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease, 2022, Cell
  • Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation, 2021, Journal of Clinical Oncology
  • Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment, 2022, Science Translational Medicine
  • Multi-faceted role of LRP1 in the immune system, 2023, Frontiers in Immunology
  • Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia, 2020, Leukemia

The scientist frequently publishes in journals such as Blood, bioRxiv (Cold Spring Harbor Laboratory), Cytotherapy, Cancer Research, and Leukemia.

Collaborations are a significant aspect of their research. Frequent co-authors include Gheath Alatrash, Lisa S. St. John, Elizabeth J. Shpall, Céline Kerros, and Jin S. Im.

Jeffrey J. Molldrem has been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 2014.

Best Publications

  • PD-L1 Expression in Triple-Negative Breast Cancer

    Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

    Jeffrey J. Molldrem;Peter P. Lee;Changqing Wang;Kyrie Felio

  • Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

    Ann M. Leen;G. Doug Myers;Uluhan Sili;M. Helen Huls

  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

    Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell

  • Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

    J. Molldrem;S. Dermime;K. Parker;Yin Zheng Jiang

  • Display technologies: application for the discovery of drug and gene delivery agents.

    Anna Sergeeva;Mikhail G. Kolonin;Jeffrey J. Molldrem;Renata Pasqualini

  • Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome

    Maryalice Stetler-Stevenson;Diane C. Arthur;Nicholas Jabbour;Xiu Y. Xie

  • HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

    Yogen Saunthararajah;Ryotaro Nakamura;Jun Mo Nam;Jamie Robyn

  • Antithymocyte globulin for patients with myelodysplastic syndrome

    Jeffrey J. Molldrem;Mary Caples;Dimitrios Mavroudis;Michelle Plante

  • Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing

    Krishna V. Komanduri;Lisa S. St. John;Marcos J.G. de Lima;John McMannis

  • Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

    Patrick J. Hanley;Conrad Russell Young Cruz;Barbara Savoldo;Ann M. Leen

  • Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units

    Jeffrey J. Molldrem;Emmanuel Clave;Yin Zheng Jiang;Dimitrios Mavroudis

  • CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies

    Dimitrios Mavroudis;Elizabeth Read;Michele Cottler-Fox;Daniel Couriel

  • Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes

    Jeffrey J. Molldrem;Eric Leifer;Erkut Bahceci;Yogen Saunthararajah

  • Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

    Richard E Champlin;Issa F Khouri;Avichai Shimoni;James Gajewski

  • Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells

    Evren Ozdemir;Evren Ozdemir;Lisa S St. John;Lisa S St. John;Geraldine M Gillespie;Geraldine M Gillespie;Sarah L Rowland-Jones;Sarah L Rowland-Jones

  • Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells

    Jeffrey J. Molldrem;Peter P. Lee;Shreya Kant;Eric Wieder

  • Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.

    Stefan O. Ciurea;Peter F. Thall;Xuemei Wang;Sa A. Wang

  • Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

    John Barrett;Yogen Saunthararajah;Yogen Saunthararajah;Jeffrey Molldrem;Jeffrey Molldrem

  • Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles.

    Jeffrey J. Molldrem;Yin Zheng Jiang;Maryalice Stetler-Stevenson;Dimitrios Mavroudis

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Elizabeth A. Mittendorf
Elizabeth A. Mittendorf Brigham and Women's Hospital
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Catherine M. Bollard
Catherine M. Bollard George Washington University
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Partow Kebriaei
Partow Kebriaei The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Katayoun Rezvani
Katayoun Rezvani The University of Texas MD Anderson Cancer Center
Helen E. Heslop
Helen E. Heslop Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related nursing degrees online can open doors to rewarding healthcare careers. Many professionals look to advance their qualifications through programs like fnp to acnp bridge program online, which helps Family Nurse Practitioners specialize further in acute care settings.

Accelerated options also exist for nurses who want to fast-track their education, such as accelerated fnp programs. These programs are designed to help learners gain advanced practice skills swiftly, keeping pace with evolving healthcare needs.

Non-nurses aspiring to enter the nursing field can consider online absn programs for non nurses, which provide an accessible pathway into nursing, complementing knowledge in immunology and patient care.

It is important to note that salaries can vary greatly depending on location and specialization. For instance, consulting data on dnp salary by state helps prospective students understand the financial outlook of pursuing advanced degrees like a Doctor of Nursing Practice across the USA.

Best Scientists Citing Jeffrey J. Molldrem

Trending Scientists

Recently Published Articles